1
|
Tisi M, Mares V, Schreiber J, Englbrecht FS, Rühm W. Geant4 Monte Carlo simulation study of the secondary radiation fields at the laser-driven ion source LION. Sci Rep 2021; 11:24418. [PMID: 34952912 PMCID: PMC8709851 DOI: 10.1038/s41598-021-03897-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Accepted: 12/09/2021] [Indexed: 11/09/2022] Open
Abstract
At the Center for Advanced Laser Applications (CALA), Garching, Germany, the LION (Laser-driven ION Acceleration) experiment is being commissioned, aiming at the production of laser-driven bunches of protons and light ions with multi-MeV energies and repetition frequency up to 1 Hz. A Geant4 Monte Carlo-based study of the secondary neutron and photon fields expected during LION's different commissioning phases is presented. Goal of this study is the characterization of the secondary radiation environment present inside and outside the LION cave. Three different primary proton spectra, taken from experimental results reported in the literature and representative of three different future stages of the LION's commissioning path are used. Together with protons, also electrons are emitted through laser-target interaction and are also responsible for the production of secondary radiation. For the electron component of the three source terms, a simplified exponential model is used. Moreover, in order to reduce the simulation complexity, a two-components simplified geometrical model of proton and electron sources is proposed. It has been found that the radiation environment inside the experimental cave is either dominated by photons or neutrons depending on the position in the room and the source term used. The higher the intensity of the source, the higher the neutron contribution to the total dose for all scored positions. Maximum neutron and photon ambient dose equivalent values normalized to 109 simulated incident primaries were calculated at the exit of the vacuum chamber, where values of about 85 nSv (109 primaries)-1 and 1.0 μSv (109 primaries)-1 were found.
Collapse
Affiliation(s)
- M Tisi
- Institute of Radiation Medicine, Helmholtz Zentrum München, Neuherberg, Germany.
| | - V Mares
- Institute of Radiation Medicine, Helmholtz Zentrum München, Neuherberg, Germany
| | - J Schreiber
- Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität, Garching bei München, Germany
- Max-Planck-Institute for Quantum Optics, Garching bei München, Germany
| | - F S Englbrecht
- Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität, Garching bei München, Germany
| | - W Rühm
- Institute of Radiation Medicine, Helmholtz Zentrum München, Neuherberg, Germany
| |
Collapse
|
2
|
Wochnik A, Stolarczyk L, Ambrožová I, Davídková M, De Saint-Hubert M, Domański S, Domingo C, Knežević Ž, Kopeć R, Kuć M, Majer M, Mojżeszek N, Mares V, Martínez-Rovira I, Caballero-Pacheco MÁ, Pyszka E, Swakoń J, Trinkl S, Tisi M, Harrison R, Olko P. Out-of-field doses for scanning proton radiotherapy of shallowly located paediatric tumours-a comparison of range shifter and 3D printed compensator. Phys Med Biol 2021; 66:035012. [PMID: 33202399 DOI: 10.1088/1361-6560/abcb1f] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The lowest possible energy of proton scanning beam in cyclotron proton therapy facilities is typically between 60 and 100 MeV. Treatment of superficial lesions requires a pre-absorber to deliver doses to shallower volumes. In most of the cases a range shifter (RS) is used, but as an alternative solution, a patient-specific 3D printed proton beam compensator (BC) can be applied. A BC enables further reduction of the air gap and consequently reduction of beam scattering. Such pre-absorbers are additional sources of secondary radiation. The aim of this work was the comparison of RS and BC with respect to out-of-field doses for a simulated treatment of superficial paediatric brain tumours. EURADOS WG9 performed comparative measurements of scattered radiation in the Proteus C-235 IBA facility (Cyclotron Centre Bronowice at the Institute of Nuclear Physics, CCB IFJ PAN, Kraków, Poland) using two anthropomorphic phantoms-5 and 10 yr old-for a superficial target in the brain. Both active detectors located inside the therapy room, and passive detectors placed inside the phantoms were used. Measurements were supplemented by Monte Carlo simulation of the radiation transport. For the applied 3D printed pre-absorbers, out-of-field doses from both secondary photons and neutrons were lower than for RS. Measurements with active environmental dosimeters at five positions inside the therapy room indicated that the RS/BC ratio of the out-of-field dose was also higher than one, with a maximum of 1.7. Photon dose inside phantoms leads to higher out-of-field doses for RS than BC to almost all organs with the highest RS/BC ratio 12.5 and 13.2 for breasts for 5 and 10 yr old phantoms, respectively. For organs closest to the isocentre such as the thyroid, neutron doses were lower for BC than RS due to neutrons moderation in the target volume, but for more distant organs like bladder-conversely-lower doses for RS than BC were observed. The use of 3D printed BC as the pre-absorber placed in the near vicinity of patient in the treatment of superficial tumours does not result in the increase of secondary radiation compared to the treatment with RS, placed far from the patient.
Collapse
Affiliation(s)
- A Wochnik
- Institute of Nuclear Physics PAN, Radzikowskiego 152, Krakow 31-342, Poland
| | - L Stolarczyk
- Institute of Nuclear Physics PAN, Radzikowskiego 152, Krakow 31-342, Poland.,Skandionkliniken, von Kraemers Allé 26, Uppsala 752 37, Sweden.,Dansk Center for Partikelterapi, Palle Juul-Jensens Boulevard 25, 8200 Aarhus N, Denmark
| | - I Ambrožová
- Department of Radiation Dosimetry, Nuclear Physics Institute Czech Academy of Sciences, Prague CZ-250 68 Řež, Czech Republic
| | - M Davídková
- Department of Radiation Dosimetry, Nuclear Physics Institute Czech Academy of Sciences, Prague CZ-250 68 Řež, Czech Republic
| | - M De Saint-Hubert
- Belgium Nuclear Research Centre (SCK CEN), Boeretang 200, Mol BE-2400, Belgium
| | - S Domański
- National Centre for Nuclear Research, Otwock-Świerk 05-400, Poland
| | - C Domingo
- Departament de Física, Universitat Autònoma de Barcelona (UAB), Bellaterra E-08193, Spain
| | - Ž Knežević
- Ruđer Bošković Institute, Bijenička c. 54, Zagreb 10000, Croatia
| | - R Kopeć
- Institute of Nuclear Physics PAN, Radzikowskiego 152, Krakow 31-342, Poland
| | - M Kuć
- National Centre for Nuclear Research, Otwock-Świerk 05-400, Poland
| | - M Majer
- Ruđer Bošković Institute, Bijenička c. 54, Zagreb 10000, Croatia
| | - N Mojżeszek
- Institute of Nuclear Physics PAN, Radzikowskiego 152, Krakow 31-342, Poland
| | - V Mares
- Helmholtz Zentrum München, Institute of Radiation Medicine, Ingolstädter Landstraße 1, Neuherberg 85764, Germany
| | - I Martínez-Rovira
- Departament de Física, Universitat Autònoma de Barcelona (UAB), Bellaterra E-08193, Spain
| | - M Á Caballero-Pacheco
- Departament de Física, Universitat Autònoma de Barcelona (UAB), Bellaterra E-08193, Spain
| | - E Pyszka
- Institute of Nuclear Physics PAN, Radzikowskiego 152, Krakow 31-342, Poland
| | - J Swakoń
- Institute of Nuclear Physics PAN, Radzikowskiego 152, Krakow 31-342, Poland
| | - S Trinkl
- Helmholtz Zentrum München, Institute of Radiation Medicine, Ingolstädter Landstraße 1, Neuherberg 85764, Germany.,Technische Universität München, Physik-Department, Garching 85748, Germany
| | - M Tisi
- Helmholtz Zentrum München, Institute of Radiation Medicine, Ingolstädter Landstraße 1, Neuherberg 85764, Germany
| | - R Harrison
- University of Newcastle upon Tyne, Tyne and Wear, Newcastle upon Tyne NE1 7RU, United Kingdom
| | - P Olko
- Institute of Nuclear Physics PAN, Radzikowskiego 152, Krakow 31-342, Poland
| |
Collapse
|
3
|
Cappuzzello E, Pietà AD, Palmerini P, Sommaggio R, Astori G, Chieregato K, Perbellini O, Tisi M, Visco C, Ruggeri M, Rosato A. Adoptive cell therapy of hematological malignancies using cytokine-induced killer cells retargeted with monoclonal antibodies. Cytotherapy 2020. [DOI: 10.1016/j.jcyt.2020.03.215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Palmerini P, Cappuzzello E, Pietà AD, Sommaggio R, Astori G, Chieregato K, Perbellini O, Tisi M, Visco C, Ruggeri M, Rosato A. Optimization of a gmp-grade large-scale expansion protocol for cytokine-induced killer cells using gas-permeable static culture flasks. Cytotherapy 2020. [DOI: 10.1016/j.jcyt.2020.03.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Facchinelli D, Boninsegna E, Sina S, Borin A, Tisi M, Piazza F, Scapinello G, Maiolo E, Merli M, Stefani P, Basso M, Parisi A, Manfrin E, Krampera M, Visco C, Tecchio C. PRIMARY PANCREATIC LYMPHOMA: CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND OUTCOME IN A MULTICENTRIC ITALIAN EXPERIENCE. Hematol Oncol 2019. [DOI: 10.1002/hon.131_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
| | | | - S. Sina
- Diagnostics; Patology and Diagnostics; Verona Italy
| | - A. Borin
- Surgery; General and Pancreatic Surgery; Verona Italy
| | - M. Tisi
- Department of Medicine; Hematology Unit; Vicenza Italy
| | - F. Piazza
- Department of Medicine; Hematology Unit; Padova Italy
| | - G. Scapinello
- Department of Medicine; Hematology Unit; Padova Italy
| | - E. Maiolo
- Department of Medicine; Hematology Unit, Roma
| | - M. Merli
- Department of Medicine; Hematology Unit; Varese Italy
| | - P. Stefani
- Department of Medicine; Hematology Unit; Treviso Italy
| | - M. Basso
- Department of Medicine; Hematology Unit; Castelfranco Veneto Italy
| | - A. Parisi
- Diagnostics; Patology and Diagnostics; Verona Italy
| | - E. Manfrin
- Diagnostics; Patology and Diagnostics; Verona Italy
| | - M. Krampera
- Department of Medicine; Hematology Unit; Verona Italy
| | - C. Visco
- Department of Medicine; Hematology Unit; Verona Italy
| | - C. Tecchio
- Department of Medicine; Hematology Unit; Verona Italy
| |
Collapse
|
6
|
Visco C, Di Rocco A, Tisi M, Morello L, Evangelista A, Zilioli V, Rusconi C, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Marin-Niebla A, McCulloch R, Gini G, Perrone T, Nassi L, Pennese E, Stefani P, Cox M, Bozzoli V, Fabbri A, Polli V, Ferrero S, De Celis I, Sica A, Arcaini L, Balzarotti M, Rule S, Vitolo U. OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.16_2629] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C. Visco
- Medicine, Section of Hematology; University of Verona; Verona Italy
| | - A. Di Rocco
- Translational and Precision Medicine; Sapienza University of Rome; Rome Italy
| | - M.C. Tisi
- Medicine, Section of Hematology; University of Verona; Verona Italy
| | - L. Morello
- Hematology; Humanitas Clinical and Research Center; Rozzano Italy
| | - A. Evangelista
- Clinical Epidemiology; Città della Salute e della Scienza and CPO Piemonte; Torino Italy
| | - V.R. Zilioli
- Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - C. Rusconi
- Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - S. Hohaus
- Institute of Hematology, Policlinico Gemelli Foundation; Catholic University of the Sacred Heart; Roma Italy
| | - R. Sciarra
- Haematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - A. Re
- Hematology; Spedali Civili; Brescia Italy
| | - C. Tecchio
- Medicine, Section of Hematology and Bone Marrow Transplant; University of Verona; Verona Italy
| | - A. Chiappella
- Hematology; Città della salute e della scienza University Hospital; Torino Italy
| | - A. Marin-Niebla
- Hematology; Vall d'Hebron Institut d'Oncologia (VHIO); Barcelona Spain
| | - R. McCulloch
- Haematology; University of Plymouth and Derriford Hospital; Plymouth United Kingdom
| | - G. Gini
- Hematology, Department of Clinical and Molecular Sciences; Marche Polytechnic University; Ancona Italy
| | - T. Perrone
- Hematology; University of Bari; Bari Italy
| | - L. Nassi
- Hematology; Azienda Ospedaliero-Universitaria Maggiore della Carità; Novara Italy
| | - E. Pennese
- Hematology; UOSD "Centro Diagnosi e Terapia dei Linfomi"; PO Santo Spirito Pescara Italy
| | - P.M. Stefani
- Hematology; Ca' Foncello Hospital; Treviso Italy
| | - M.C. Cox
- Hematology; AOU Sant'Andrea; Rome Italy
| | | | - A. Fabbri
- Hematology; Azienda Ospedaliera Universitaria Senese & University of Siena; Siena Italy
| | - V. Polli
- Hematology; Ospedale degli Infermi; Rimini Italy
| | - S. Ferrero
- Molecular Biotechnologies and Health Sciences; University of Torino/AOU "Città della Salute e della Scienza di Torino"; Torino Italy
| | - I.A. De Celis
- Hematology; AUSLL/IRCCS Santa Maria Nuova Hospital; Reggio Emilia Italy
| | - A. Sica
- Hematology; Policlinico di Napoli; Napoli Italy
| | - L. Arcaini
- Haematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - M. Balzarotti
- Hematology; Humanitas Clinical and Research Center; Rozzano Italy
| | - S. Rule
- Haematology; University of Plymouth and Derriford Hospital; Plymouth United Kingdom
| | - U. Vitolo
- Hematology; Città della salute e della scienza University Hospital; Torino Italy
| |
Collapse
|
7
|
Ghione P, Cavallo F, Visco C, Chen Z, Nicolosi M, Castellino A, Tisi M, Dogliotti I, Boccadoro M, Leonard J, Vitolo U, Martin P. Retrospective analysis on R-DHAP/OX and ASCT as salvage treatment for relapsed/refractory high-risk follicular lymphoma. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Ghione
- Department of Molecular Biotechnologies and Health Sciences; Universita' di Torino; Torino Italy
| | - F. Cavallo
- Department of Molecular Biotechnologies and Health Sciences; Universita' di Torino; Torino Italy
| | - C. Visco
- Cell Therapy and Hematology; San Bortolo Hospital; Vicenza Italy
| | - Z. Chen
- Division of Biostatistics and Epidemiology; Weill Cornell Medicine; New York New York USA
| | - M. Nicolosi
- Hematology 2, Citta' della Salute e della Scienza di Torino; Torino Italy
| | - A. Castellino
- Hematology 2, Citta' della Salute e della Scienza di Torino; Torino Italy
| | - M.C. Tisi
- Cell Therapy and Hematology; San Bortolo Hospital; Vicenza Italy
| | - I. Dogliotti
- Department of Molecular Biotechnologies and Health Sciences; Universita' di Torino; Torino Italy
| | - M. Boccadoro
- Department of Molecular Biotechnologies and Health Sciences; Universita' di Torino; Torino Italy
| | - J.P. Leonard
- Hematology and Medical Oncology, Weill Cornell Medicine; New York New York USA
| | - U. Vitolo
- Hematology 2, Citta' della Salute e della Scienza di Torino; Torino Italy
| | - P. Martin
- Hematology and Medical Oncology, Weill Cornell Medicine; New York New York USA
| |
Collapse
|
8
|
Bussu F, Hohaus S, Bastanza G, Bozzoli V, Tisi M, Martini M, Paludetti G, Almadori G. Clinical and prognostic features of lymphomas arising in the head and neck region: Our experience of preferential association of different histotypes with various sites of origin in ninety patients. Clin Otolaryngol 2013; 38:248-53. [DOI: 10.1111/coa.12090] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/04/2012] [Indexed: 11/28/2022]
Affiliation(s)
- F. Bussu
- Institute of Otolaryngology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - S. Hohaus
- Institute of Haematology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - G. Bastanza
- Institute of Otolaryngology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - V. Bozzoli
- Institute of Haematology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - M.C. Tisi
- Institute of Haematology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - M. Martini
- Institute of Histopatology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - G. Paludetti
- Institute of Otolaryngology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - G. Almadori
- Institute of Otolaryngology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| |
Collapse
|